Circulating tumor DNA-based minimal residual disease detection and its clinical utility in early-stage cancer: a systematic review and meta-analysis
Blood tests detecting leftover cancer cells after surgery help doctors spot recurrence earlier and adjust follow-up care.
This systematic review and meta-analysis comprehensively evaluates ctDNA-based minimal residual disease detection across early-stage cancers. The findings confirm strong prognostic utility of ctDNA MRD, supporting its potential integration into post-surgical surveillance protocols.
What the study was
- Study design
- Systematic review and meta-analysis
- Population
- Early-stage cancer patients with ctDNA MRD assessment
- Category
- Early Detection
- Maturity
- Validated
Why it surfaced
Meta-analysis providing high-level evidence for ctDNA MRD in early cancer — directly relevant to early detection and surveillance. Study design (SR/MA) is gold standard.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.